EarliPoint Health receives expanded FDA clearance for autism assessment in children up to age 8.

Read Release →

Rethinking The Autism Diagnosis Process

I’ve been thinking a lot lately about a question that sparked an incredible—and at times, heated—debate on a LinkedIn post I recently wrote: Should ABA providers be the ones diagnosing autism?

The feedback was overwhelming, ranging from enthusiastic support to deep concern about ethical boundaries. When I see this many thoughtful clinicians disagreeing, it tells me we’re at a major turning point for the field. I wanted to use this space to dive deeper into the conversation, specifically addressing the points raised by the community.

The Reality of the “Wait and See” Trap

For most families I talk to, the diagnostic process feels like an exhausting obstacle course. They might wait months—sometimes over a year—just for an evaluation. As LinkedIn commenters rightfully pointed out, waiting for diagnoses can have long-term, life-long consequences. These delays aren’t just an inconvenience; they represent lost opportunities during a critical developmental window.

From a systems view, it’s inefficient. From a family view, it’s heartbreaking. This is why many LinkedIn commenters see integration as a “net gain,” noting that hospital systems already refer internally for hundreds of services without the same level of scrutiny.

The Risks: “Pseudo-Diagnoses” and Conflicts of Interest

However, we have to address the elephant in the room. Some of the most poignant pushback came from LinkedIn commenters who warned against pseudo-diagnoses that serve no purpose other than rushing kids into a clinic.

The concerns generally fall into three buckets:

  • Scope of Practice: BCBAs are experts in behavior, but they aren’t trained for the complex medical and psychological differential diagnosis required to rule out things like genetic disorders or TBI.
  • Confirmation Bias: If a clinic diagnoses a child and immediately recommends 40 hours of their own therapy, is that a clinical necessity or a sales tactic?
  • Ethical “Dual Relationships”: You can understand this concern by comparing diagnosing and treating autism to physical therapy—we don’t let PTs diagnose the musculoskeletal injuries they treat for a reason.

Shifting the Conversation: How to Evolve Responsibly

So, how do we bridge the gap between “we need faster access” and “we must protect clinical integrity”? I don’t think the answer is to stay in our silos. We shouldn’t equate “newness” with being “unethical.” We should be asking how to make this happen safely.

The Non-Negotiable Guardrails

Based on suggestions from experts and LinkedIn comments on my original post, here is what a responsible integrated model could look like:

  1. Qualified Clinicians Only: Diagnosis must be done by licensed psychologists or physicians, even if they are hosted within an ABA organization.
  2. Operational Separation: There should be a “firewall” between the diagnostic team and the intake/sales team.
  3. The “Bridge” Model: Try a fascinating “provisional behavioral classification”—a short-term bridge to get kids into early intervention while they wait for a full neuro-pediatric workup.
  4. Full Transparency: Families must be explicitly told they are under no obligation to use that provider’s therapy services just because they got their diagnosis there.

Final Thoughts

The future of autism care is moving toward a “whole-person” approach. Integrated, interdisciplinary teams should be the baseline for responsible practice, not just a trend.

The goal isn’t just to debate these new models, but to shape them. We owe it to families to provide a path that is both fast and beyond reproach.

 

Latest News

See how EarliPoint fits seamlessly into your clinical workflow.

Jamie Pagliaro brings over two decades of leadership in autism and behavioral health to his role as President and CEO of EarliPoint. Most recently, he served as Chief Operating Officer at Rethink, a leading SaaS provider supporting individuals with autism and developmental disabilities. Under his leadership, Rethink’s behavioral health division became the company’s largest business unit, serving thousands of clinicians and driving scalable, tech-enabled care delivery.

Earlier in his career, Jamie was Executive Director of the New York Center for Autism Charter School, the first public charter school in New York State dedicated to children with autism. At EarliPoint, he leads the company’s mission to bring breakthrough science to the front lines of care—empowering providers, families, and health systems with earlier answers and better outcomes.

Jamie Pagliaro

President & Chief Executive Officer

Dr. Ami Klin is a globally recognized leader in autism research and early detection. As Director of the Marcus Autism Center and Division Chief of Autism and Developmental Disabilities at Emory University School of Medicine, he has dedicated his career to understanding how young children engage with the social world—and how subtle disruptions in attention can signal developmental differences. His pioneering work in eye-tracking science led to the development of EarliPoint™ Evaluation, the first FDA-authorized tool to objectively assess autism in children as young as 16 months.
At EarliPoint, Dr. Klin drives clinical strategy and innovation, ensuring that families and clinicians worldwide have access to timely, science-based insights that enable earlier, more personalized intervention. His career reflects a deep commitment to transforming how society supports children with autism—starting with the earliest signs.

Ami Klin, PhD

Chief Clinical Officer & Co‑Founder